Stay updated with breaking news from Triple Combination Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Triple combination therapy has shown promise for stage 4 prostate cancer patients. But doctors also emphasize the critical importance of your mindset.
The study states that triple combination therapy can help in making mucus less sticky and reducing lung inflammation. | Health
May 16, 2021 Ultrasound-based renal denervation (Paradise; ReCor Medical) significantly lowers systolic blood pressure when compared with a sham procedure in patients with resistant hypertension treated on a background of antihypertensive therapy, the RADIANCE-HTN TRIO shows. Renal denervation reduced daytime ambulatory systolic blood pressure by 8.0 mm Hg compared with a 3.0-mm Hg reduction observed in patients treated with the sham procedure, a median between-group difference of 4.5 mm Hg ( P = 0.02). Additionally, there were significant between-group reductions in 24-hour ambulatory systo...
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study designed to assess COM701, Compugen's first-in-class anti-PVRIG antibody, in combination with Opdivo® in selected cancer indications. Study initiation is expected in the second quarter of 2021.